Regeneron Pharmaceuticals Inc (REGN) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, inclu...
Regeneron Pharmaceuticals Inc's revenue increased 1.0% year over year, from $14.20B to $14.34B.
Net income increased 2.1% over the same period, from $4.41B to $4.50B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 195% in total.
Total debt remained relatively stable at $1.99B.
The debt-to-equity ratio stands at 0.06, indicating a conservative leverage profile.
Operating cash flow grew 12.6% to $4.98B.
Regeneron Pharmaceuticals Inc maintains a strong net profit margin of 31.4%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $9.68B+53.2% | $2.79B | $8.38B | $3.07B | $3.50B | $32.16B | $1.98B | $24.90B |
| Q1 FY2024 | $3.15B-67.5% | $722.0M | $2.71B | $751.4M | $1.51B | $34.37B | $1.98B | $26.99B |
| Q2 FY2024 | $6.69B+112.8% | $2.15B | $5.78B | $1.82B | $1.87B | $36.09B | $1.98B | $28.21B |
| Q3 FY2024 | $10.41B+55.6% | $3.49B | $9.01B | $3.00B | $3.16B | $37.44B | $1.98B | $29.33B |
| Q1 FY2025 | $3.03B-70.9% | $808.7M | $2.56B | $591.7M | $1.05B | $37.55B | $1.98B | $29.39B |
| Q2 FY2025 | $6.70B+121.4% | $2.20B | $5.71B | $1.67B | $2.19B | $38.22B | $1.99B | $29.94B |
| Q3 FY2025 | $10.46B+56.0% | $3.66B | $8.94B | $2.70B | $3.81B | $40.17B | $1.99B | $30.96B |
| Q1 FY2026 | $3.61B-65.5% | $727.2M | $2.94B | $642.9M | $1.08B | $40.87B | $1.99B | $31.42B |